uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta Sells 26,727 Shares

uniQure (NASDAQ:QURE) CEO Matthew C. Kapusta sold 26,727 shares of the stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $10.70, for a total value of $285,978.90. Following the transaction, the chief executive officer now owns 571,188 shares in the company, valued at $6,111,711.60. The trade was a 4.47 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

uniQure Price Performance

QURE stock opened at $12.07 on Friday. The company has a debt-to-equity ratio of 0.92, a quick ratio of 6.51 and a current ratio of 6.51. The business has a 50-day simple moving average of $15.12 and a two-hundred day simple moving average of $9.75. The company has a market capitalization of $588.33 million, a P/E ratio of -2.43 and a beta of 0.38. uniQure has a 52-week low of $3.73 and a 52-week high of $19.18.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of QURE. RTW Investments LP purchased a new stake in uniQure in the 3rd quarter valued at $49,000. China Universal Asset Management Co. Ltd. grew its stake in shares of uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 3,663 shares in the last quarter. Atria Investments Inc bought a new stake in shares of uniQure in the 3rd quarter worth $53,000. Quarry LP purchased a new stake in shares of uniQure in the third quarter valued at about $58,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of uniQure during the third quarter valued at about $69,000. Institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on QURE shares. Leerink Partners boosted their target price on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Mizuho upped their price objective on shares of uniQure from $7.00 to $20.00 and gave the company a “neutral” rating in a report on Thursday, December 19th. The Goldman Sachs Group increased their price objective on shares of uniQure from $9.00 to $20.00 and gave the stock a “neutral” rating in a research report on Thursday, December 12th. HC Wainwright boosted their target price on uniQure from $25.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, January 27th. Finally, StockNews.com upgraded uniQure to a “sell” rating in a report on Wednesday, February 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $40.00.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.